Company* |
University/ |
Type Of |
Product Area | Details (Date) |
Acceptys Inc.* |
University of Wurzburg (Germany) |
Research agreement |
University researchers will further characterize about 650 anticancer human antibodies |
The deal followed one in which Acceptys acquired rights to develop antibodies from OncoMab GmbH, which was formed from university research (12/23) |
Accentia Bio- |
Mayo Foundation for Medical Education and Research |
Option agreement |
The option covers a method of using anti-fungals applied intranasally for treating chronic sinusitis |
Accentia has exclusive rights to negotiate a license until Dec. 6, 2006; the method covers all anti-fungals except amphotericin B (12/15) |
ACE BioSciences |
Aeras Global TB Vaccine Foundation |
Collaboration |
ACE will support characterization of a BCG- based tuberculosisvaccine |
ACE will identify and characterize proteins in the second-generation vaccine Aeras is developing; terms were not disclosed (12/19) |
Affymetrix Inc. |
Duke University |
Collaboration |
Five-year deal to analyze genomic information across large patient samples |
Duke researchers will use Affymetrix microarray technology to develop new applications for translational research projects; the initial focus is on cancer and cardiovascular disease (1/9) |
Affymetrix Inc. |
Imperial College London and the Medical Research Council (UK) |
Collaboration |
To discover genetic variations associated with cancer, diabetes and cardiovascular disease |
College and MRC researchers will use Affymetrix's GeneChip technology in the deal, which is part of Affymetrix's translational medicine program (12/14) |
Amorfix Life |
University of Toronto (Canada) |
License agreement |
Amorfix got worldwide rights to targets on the protein superoxide dismutase-1 |
Amorfix also got a five-year option to acquire the technology, which will be tested against amyotrophic lateral sclerosis and other neurodegenerative diseases (2/2) |
Aphios Corp.* |
Boston University Medical School |
License agreement |
Aphios got rights to a nontoxic vitamin D analogue |
The compound is being developed for prostate cancer; terms of the deal were not disclosed (12/13) |
Artemis |
Medical Research Council Protein Phosphorylation Unit (UK) |
License agreement |
Artemis got rights to use and distribute certain genetically engineered mouse models |
Artemis will distribute the kinase models to companies and instituions and can use them in its programs; terms were not disclosed (12/5) |
AvidBiotics |
University of California at San Diego |
License agreement |
AvidBiotics got worldwide rights to protein scaffold technology |
The technology centers on a ligand-binding protein scaffold that accommodates 10 trillion sequences (2/23) |
Biocortech* |
Columbia University |
Collaboration |
Deal for research involving the mRNA editing of the serotonergic receptor |
They also plan to identify therapeutic targets; the focus is on treating depression (2/23) |
Bioheart Inc.* |
Cleveland Clinic |
License agreement |
Bioheart got rights to technology related to the repair of scarred heart tissue damaged from a heart attack |
The patent applications cover methods of repairing tissue by transplanting muscle stem cells that express therapeutic proteins capable of recruiting other stem cells to the area (2/20) |
BioLineRx |
The Technion Research and Development Foundations (Israel) |
License agreement |
BioLineRx got rights to the antibiotic candidate BL-2060 |
The antibacterial peptide is designed to kill bacteria without causing hemolysis; terms were not disclosed (1/16) |
BioLineRx |
Tel Aviv University (Israel) |
License agreement |
BioLineRx got rights to BL-2050, an agent for treating peripheral vascular disease |
The agent acts through a non- VEGF pathway; terms of the deal were not disclosed (1/16) |
BioVeris Corp. |
University of Massachusetts at Amherst |
License agreement |
BioVeris exercised its option to exclusively license a vaccine candidate for Chlamydia |
UMA gets a $75,000 license fee and potential milestone payments, as well as royalties on any resulting sales (12/6) |
BioVeris Corp. |
Jewish General Hospital (Canada) |
License agreement |
BioVeris got exclusive rights to use a JGH database containing infectious disease information |
The database has demographic data and the serologic status on an immigrant population; BioVeris paid a $50,000 license fee and will sponsor $400,000 of research at JGH over three years (11/21) |
Calando |
National Cancer Institute |
Collaboration |
The deal focuses on developing RNAi therapeutics for treating neuroblastoma |
They will share responsibilities in the research program, which is expected to run at least three years; a CRADA covering the deal was being finalized (2/3) |
Callisto |
University of Texas M.D. Anderson Cancer Center |
License agreement |
Callisto got rights to a new class of cancer drugs called Degrasyns |
The agents are designed to induce tumor cell death; terms of the deal were not disclosed (1/25) |
Can-Fite |
National Institutes of Health |
CRADA |
Deal to identify agonists of the adenosine A3 receptor |
The goal is to identify agents for treating autoimmune diseases and cancer (1/24) |
Cellegy |
Contraceptive Research and Development Organization |
License agreement |
CONRAD licensed rights to Cellegy's entire microbicide pipeline |
The nonexclusive agreement covers the developing world; products include Savvy, UC-781 and Cyanovirin-N (2/1) |
Cel-Sci Corp. |
National Institute of Allergy and Infectious Diseases |
Cooperative agreement |
Deal to test Cel-Sci's anti- infective drug CEL-1000 in animal models against the H5N1 avian flu virus |
The agent is believed to activate immune responses; terms of the deal were not disclosed (12/5) |
Cepheid Inc. |
Public Health Agency of Canada's National Microbiology Laboratory |
Collaboration |
Deal to develop in-field nucleic acid assays for Ebola, Marburg and Lassa fever viruses |
They will use Cepheid's Gene- Xpert technology in the effort; Cepheid will have rights to resulting technology (2/14) |
Ceragenix |
Centers for Disease Control and Prevention |
CRADA |
Deal to evaluate Ceragenix's Ceracide for preventing bacterial biofilm growth on medical devices |
The antimicrobial coating will be evaluated in the CDC's Biofilm Reactor; terms of the deal were not disclosed (2/8) |
Chemokine |
University of Texas M.D. Anderson Cancer Center |
Agreement |
The cancer center will conduct tests of Chemokine's CTCE- 908 product |
The agent will be studied for its ability to inhibit metastasis of a human breast cancer in preclinical models (2/21) |
Chemokine |
Dana-Farber Cancer Institute |
Material transfer agreement |
Deal under which Chemokine will supply its CTCE-9908 product to Dana-Farber |
The institute will investigate the drug's ability to inhibit growth of human brain cancer cells in pre-clinical experiments (2/16) |
Chemokine |
National Cancer Institute |
Material transfer agreement |
Deal under which Chemokine will supply its CTCE-9908 product to the NCI |
The NCI will investigate the role of CTCE- 908 in the pathology of primary effusion lymphoma; terms were not disclosed (2/13) |
Ciphergen |
University of Texas Medical Branch at Galveston |
Collaboration |
Deal to apply Ciphergen technologies to UTMB clinical samples for liver disease research |
They intend to develop a diagnostic blood test for measuring the progress of liver disease; Ciphergen gets first right to license resulting products (11/21) |
Clinical Data Inc. |
University of Pittsburgh Cancer Institute |
Collaboration |
Deal to perform a metabolomics study in lung cancer patients |
The goal of the pilot study is to evaluate the suitability of meta-bolomics for cancer detection and screening (1/12) |
CombiMatrix |
U.S. Air Force Research Laboratory |
CRADA |
Deal to develop a miniaturized device for monitoring the health status of military personnel |
They will use CombiMatrix's CustomArray technology to develop a device capable of analyzing multiple biomarkers (2/23) |
CombiMatrix |
University of Colorado Health Sciences Center |
Agreement |
Deal under which university researchers can purchase microarray technology |
The nonexclusive deal was made under CombiMatrix's CombiCore access program; terms were not disclosed (1/6) |
CombiMatrix |
University of California at Los Angeles |
Collaboration |
Deal to develop a gene-based test for the diagnosis of malignant melanoma |
UCLA researchers also will provide patient samples for the development and validation phase of the project (12/7) |
Corautus |
Caritas St. Elizabeth's Medical Center |
Agreement |
Corautus will provide its VEGF-2 product for a trial being run by CSEMC |
The Phase I trial, funded by an NIH grant, is focused on critical limb ischemia (1/11) |
Crucell NV |
Walter Reed Army Institute of Research |
CRADA |
Deal to evaluate Crucell's PER.C6 technology for development of vaccines against certain flaviviruses |
WRAIR will evaluate the technology in vaccines against dengue fever and Japanese encephalitis; terms were not disclosed (12/22) |
Crucell NV |
Saskatchewan Research Council (Canada) |
Manufacturing agreement |
SRC got rights to sell PER.C6 cell line services in Canada; SRC also got a license to the technology |
The services are for manufacturing gene therapy and vaccine products; Crucell gets a license fee, annual maintenance fees and royalties on sales (12/22) |
CytoCore Inc. |
University Hospitals of Cleveland |
License agreement |
CytoCore got rights to a drug delivery system |
The system is designed to allow application of approved drugs to existing cervical lesions (2/23) |
CytoCore Inc. |
University Hospitals of Cleveland |
License agreement |
CytoCore got rights to the cancer biomarker CGI5 |
Terms of the deal on the apoptosis marker were not disclosed (2/17) |
CytRx Corp. |
University of Massachusetts Medical School |
Expanded agreement |
The new deal covers drug targets that regulate insulin activity in fat cells |
CytRx licensed the targets, which were discovered in an existing collaboration between it and UMMS (12/15) |
Eurand |
Universities of Milan and Sassari (both in Italy) |
License agreement |
Eurand got an option to develop a class of analgesic compounds |
They will collaborate to develop and evaluate the five compounds for the treatment of pain (1/24) |
Exelixis Plant |
Washington State University Research Foundation |
License agreement |
Exelixis will use its technologies to develop methods for producing paclitaxel and taxane intermediates |
Exelixis has advanced developments of its taxane cell factory program under a previous license from WSURF; terms were not disclosed (12/28) |
454 Life |
The Broad Institute |
Collaboration |
The institute will conduct genomic studies relating to the genetic basis for complex diseases |
The institute will use a genome sequencer system from 454 in the effort; terms of the deal were not disclosed (12/19) |
Galapagos NV |
Cancer Research Technology (UK) |
Collaboration |
Galapagos will provide medicinal chemistry services for CRT anti-cancer drug programs |
CRT will fund the work for four scientists at Galapagos' service division, BioFocus, through 2006 (1/19) |
Gammacan |
Tel Hashomer Medical Research Infrastructure and treatment |
Research and license agreement |
To explore mechanisms of action of IVIg and its uses in cancer |
Terms of the deal were not disclosed (12/20) |
GeoPharma Inc.* |
University of Florida |
License agreement |
GeoPharma got rights to a compound for treating primary or idiopathic pulmonary hypertension |
The compound is a synthetic peptide in preclinical testing; terms of the deal were not disclosed (1/31) |
Hemispherx |
Canadian Department of National Defence |
Research agreement |
To evaluate antiviral efficacy of the company's Ampligen and Alferon products |
Defence R&D Canada is testing the products against influenza in an effort focused on the bird flu (11/29) |
HemoBioTech |
Texas Tech University Health Sciences Center |
Sponsored research agreement |
The agreement centers on the manufacture of clinical-grade HemoTech |
They entered the third-stage of an agreement on the blood substitute product; terms were not disclosed (1/18) |
Humanetics |
Henry M. Jackson Foundation for the Advancement of Military Medicine Inc. |
License agreement |
Deal to develop the oral agent BIO300 for protecting the immune system against radiation exposure |
Humanetics assumed responsibility for continued testing, development and commercialization of the product; terms were not disclosed (12/8) |
Humanetics |
Mount Sinai School of Medicine |
License agreement |
Humanetics got rights to NIC5-15, a preclinical agent being developed for Alzheimer's disease |
They also agreed to a deal under which Mount Sinai will test the agent in humans; terms were not disclosed (12/1) |
Hybrigenics |
Genethon (France) |
Collaboration |
Genethon will use Hybrigenics technology in research in muscle cell proteins and their interaction |
Hybrigenics will use screening and protein interaction mapping software in the effort; Genethon will own resulting data; terms were not disclosed (12/21) |
Illumina Inc. |
Center for Inherited Disease Research |
Collaboration |
CIDR will use Ilumina genotyping technology in a pilot study in Type II diabetes |
One goal is to evaluate the technology for possible adoption as the standard platform for CIDR's genome-wide association service (1/11) |
Immtech |
Tulane University |
License agreement |
Immtech got rights to a class of aminoquinoline drugs for treating and diagnosing infectious diseases |
The lead compound, AQ13, is targeted for the treatment of, and as a prophylaxis for, malaria; terms of the exclusive deal were not disclosed (2/10) |
Immusol Inc.* |
Baylor College of Medicine |
License agreement |
Immusol got rights to an oncolytic viral therapy that uses herpes simplex viruses against cancer |
Terms of the exclusive, worldwide deal were not disclosed (2/1) |
Innovive |
Memorial Sloan- Kettering Cancer Center |
License agreement |
Innovive got rights to a WT1 heteroclitic peptide immuno- therapeutic, INNO-305 |
Phase I trials are expected to start in the first half of 2006; the agent targets most leukemias and certain solid tumors (1/9) |
Invitrogen |
Families of Spinal Muscular Atrophy |
Collaboration |
To identify targets linked to causes and symptoms of spinal muscular atrophy |
Invitrogen will use its protein microarray technology in the intial stages of the deal; terms were not disclosed (12/21) |
Lumera Corp. |
Medical University of South Carolina |
Agreements |
Deal to co-develop a protein chip aimed at the drug discovery and toxicology market |
Also, letter of intent calls for MUSC to purchase a Proteomic-Processor Biosensor instrument; terms were not disclosed (2/6) |
Lumera Corp. |
Harvard Medical School |
Collaboration |
Deal to develop a next- generation silicon chip substrate |
The goal is to develop 10,000- spot very high density protein arrays (1/9) |
Medicure Inc. |
Loyola University Stritch School of Medicine |
Collaboration expansion |
Deal to conduct further preclinical studies of Medicure's antithrombotic agents |
The goal is to advance a lead clinical candidate into human studies; terms of the deal were not disclosed (1/5) |
MedImmune Inc. (MEDI) |
Burnham Institute for Medical Research |
License agreement |
Deal to develop peptides targeting the EphA and EphB subfamilies of receptor tyrosine kinases |
MedImmune would develop and market any resulting products; Burnham gets an up- front fee and potential milestone and royalty payments (12/8) |
MedImmune |
Mount Sinai School of Medicine |
License agreement |
MedImmune got exclusive rights to certain reverse genetics technology |
Mount Sinai gets an up-front fee and potential milestone and royalty payments; the technology will be used to improve the efficiency of producing new influezna vaccine strains (12/7) |
Memory |
The Stanley Medical Research Institute |
Funding support |
The institute will help fund trials of Memory's MEM 1003 for treating bipolar disorder |
The neuronal L-type calcium channel modulator is nearing Phase IIa trials in that indication; Memory is eligible to receive up to $3.2M in the deal (12/20) |
Metabolon |
University of Michigan |
Collaboration |
They will work to discover disease biomarkers for prostate cancer |
The deal marks Metabolon's first project as part of the NCI's Early Detection Research Network; the project is funded by an NCI grant (11/30) |
MicroIslet |
Mayo Foundation for Medical Education and Research |
Supply agreement |
Mayo will supply pathogen- free pigs to MicroIslet for use in development of a product for diabetes |
Pig islets will be used in the MicroIslet-P product; MicroIslet also got rights to use the pigs for research and treatment in diabetes under the long-term deal (11/22) |
Minster |
University of Copenhagen and the Danish Headache Centre |
Collaboration |
Deal to investigate the use of tonabersat in the prevention of migraine with aura |
A planned Phase II trial is part of a broader deal to investigate the mechanisms underlying migraine (1/13) |
Morphotek |
National Cancer Institute |
License agreement |
Morphotek got rights to an antibody targeting mesothelin- expressing cancers |
The rights cover diagnostic and therapeutics applications; initial trials of the antibody, MORAb-009, were planned for early in 2006 (1/3) |
MultiCell |
Columbia University Medical Center |
Research agreement |
Deal to perform in vivo tests on an agent for protecting against retinal ganglion cell death |
MultiCell will fund research and have an exclusive option to resulting discoveries; the focus is on ocular neurodegenerative diseases (12/1) |
NanoMed |
University of Kentucky |
Option agreement |
NanoMed will evaluate raspberry gels for treating and preventing oral epithelial dysplasia |
NanoMed intends to start trials in humans; Ohio State University also was a party to the exclusive option agreement (12/13) |
NovaThera Ltd.* |
Imperial College London and The Texas Heart Institute |
Collaboration |
They established a program to scale up supply of human heart cells for clinical trials |
Using bioprocessor technology, the group intends to develop processes for the practical manufacture of cells for medical uses (12/12) |
Novavax Inc. |
University of Pittsburgh School of Medicine |
Collaboration |
Deal to evaluate the efficacy of virus-like particle influenza vaccines |
They also will test Novasomes as an adjuvant; studies in humans were expected to begin later in 2006 (2/15) |
Novelix |
University of Southern California |
License agreement |
Novelix got exclusive rights to a group of potential cancer therapeutics |
The lead compound, NVX-144, is expected to enter clinical trials late in 2006; terms of the deal were not disclosed (12/19) |
Open Biosystems |
Four cancer centers |
Agreement |
The centers adopted the company's short hairpin RNA technology for use in cancer research |
Duke University, the National Cancer Institute, Lee Moffitt Cancer Center and Fox Chase Cancer Center adopted the technology (12/19) |
Orion Genomics* |
University of Glasgow (UK) |
Collaboration |
To develop epigenetic biomarkers for tests to screen for cancer and to help guide treatment |
They will use Orion's methylation technologies to identify biomarkers in cancers of the lung, breast and ovaries (1/20) |
Orion Integrated |
Virginia Bioinformatics Institute |
Agreement |
Deal to develop diagnostic methods for certain viral pathogens |
Data on encephalic and hemorrhagic viruses from VBI's PathPort project will be integrated into Orion's computational tool (2/7) |
Peregrine |
Sidney Kimmel Cancer Center |
Manufacturing agreement |
Peregrine subsidiary Avid Bioservices Inc. will perform manufacturing services for SKCC |
Avid will provide services related to an antibody initially being developed for lung cancer (12/22) |
PharmaFrontiers |
Shanghai Institutes for Biological Sciences (China) |
License agreement |
PharmaFrontiers got worldwide rights to an autologous T-cell vaccine |
The vaccine targets rheumatoid arthritis; SIBS gets an up-front payment and royalties on any resulting sales(1/17) |
Point |
National Cancer Institute |
Collaboration |
Deal to evaluate Point's talabostat in pediatric patients with solid tumors |
A Phase I trial is being planned to evaluate safety and dosing of the oral agent with chemotherapy (2/14) |
PsychoGenics |
Spinal Muscular Atrophy Foundation |
Agreement extension |
Deal to establish and behaviorally phenotype transgenic in vivo models of SMA |
They also plan to test potential therapeutics using those models (2/24) |
QBI Life |
University of Wisconsin and the University of Helsinki (Finland) |
Partnership |
Deal to develop a high- throughput molecular screening platform for membrane protein targets |
The work is being funded by a $175,000 grant under the National Institutes of Health's Roadmap for Medical Research program (1/19) |
Rexahn |
University of Maryland |
Collaboration |
Deal to develop drugs for treating cancer and central nervous system diseases |
Rexahn and UM's Center for Nanomedicine and Cellular Delivery will use nanotechnologies in the effort (2/23) |
Samaritan |
Georgetown University |
License agreement |
Samaritan got exclusive rights to the use of spirostenols to treat mitochondrial disorders |
Terms of the deal were not disclosed (2/2) |
Savient |
University of California at San Diego |
License termination |
Savient ended a deal covering development of Prosaptide |
The decision was made following a failed Phase II trial in patients with HIV-associated peripheral neuropathy (12/22) |
Stem Cell |
University of Edinburgh |
Technology transfer agreement |
Deal to continue their collaboration in stem cell research |
They have collaborated since 1994; SCS retains all licenses issued under the previous deal (1/31) |
Transgene SA |
International AIDS Vaccine Initiative |
Manufacturing agreement |
Transgene will manufacture an AIDS vaccine candidate for use in clinical trials |
Transgene will use its viral vectors process in the effort; terms of the 18-month contract were not disclosed (11/17) |
20/20 |
University of Kentucky |
License agreement |
20/20 got rights to a a blood test for non-small-cell lung cancer |
20/20 intends to create a screening test for the early detection of lung cancer based on biomarkers identified by UK (12/15) |
Vertex |
Cystic Fibrosis Foundation Therapeutics Inc. |
Collaboration extension |
Vertex will continue research on "corrector" compounds that restore the function of the CFTR protein |
CFFT will provide another $22M to Vertex through early 2008; the original deal began in 2000; CFFT would get royalties on any resulting sales (1/12) |
Vical Inc. |
Stanford, Harvard and Yale universities |
License agreements |
The universities got nonexclusive access to Vical's DNA delivery technology |
The academic licenses allow free use of the technology; Vical would have the option to license resulting applications (1/24) |
ViroPharma |
Hines VA Hospital |
License agreement |
ViroPharma got rights to non-toxigenic strains of C. difficile to treat and prevent C. difficile-associated disease |
ViroPharma's initial focus is on preventing recurrence of CDAD following Vancocin treatment (2/27) |
Viropro Inc. |
Biotechnology Research Institute (Canada) |
Collaboration |
Deal to develop production procedures for biological materials and drugs |
The intent is to market recombinant proteins and a new vaccination platform (12/1) |
Xechem |
Virginia Commonwealth University |
License agreement |
Xechem got rights to a five-membered hetero-cyclic anti-sickling compound |
The compound will be studied for treating sickle cell disease; terms of the exclusive license were not disclosed (12/9) |
Xencor Inc.* |
University of Cambridge (UK) |
License agreement |
Xencor got rights to technology for creating monoclonal antibodies with enhanced potency |
The technology includes specific Fc variants that complement Xencor's XmAb engineered Fc domains; terms of the exclusive deal were not disclosed (12/14) |
Zenyth |
Ludwig Institute for Cancer Research (Germany) |
License agreement |
Zenyth got rights to antibodies that target the receptor for granulocyte-colony stimulating factor |
Zenyth also got access to antibodies and reagents developed at the institute's Melbourne branch (2/28) |
| Notes: | ||||
| This chart does not include grants or contract awards, or agreements between biotech companies and clinical trial centers. | ||||
| * Denotes privately held company. | ||||
| @ Some institutions listed have for-profit components. They are located in the U.S. unless otherwise noted. | ||||
| CRADA = Cooperative Research and Development Agreement. | ||||
| Unless otherwise noted, shares are traded on the Nasdaq exchange. | ||||
| AIM = Alternative Investment Market; AMEX = American Stock Exchange; ASX = Australian Stock Exchange; CDNX = Canadian Venture Exchange; OTC BB = Over-the-Counter Bulletin Board; TEL = Tel Aviv Stock Exchange; TSE = Toronto Stock Exchange. | ||||
